SCHEMBL5899406

SCHEMBL5899406

O=C(Cc1nc(Cc2ccncc2)cs1)C(=O)c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.31
ALDH1A1 P00352 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
MMP2 P08253 2/20 0.31
MMP13 P45452 2/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
GFER P55789 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
SLC40A1 Q9NP59 1/20 0.30
MMP1 P03956 1/20 0.30
MMP9 P14780 1/20 0.30
BCHE P06276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671667 0.91 HDAC1 (0.37) HDAC1HDAC6LMNAMMP2MMP13
SCHEMBL4676893 0.90 HDAC1 (0.42) HDAC1HDAC6KMT2ALMNAALDH1A1
SCHEMBL4671165 0.88 BCHE (0.39) KMT2AALDH1A1TDP1BCHE
SCHEMBL4675488 0.88 HDAC1 (0.39) HDAC1HDAC6
SCHEMBL4672336 0.88 HDAC6 (0.39) HDAC1HDAC6KMT2ALMNAALDH1A1
SCHEMBL4675409 0.86 KMT2A (0.37) HDAC1HDAC6KMT2ALMNABCHE
SCHEMBL5899379 0.86 HDAC1 (0.43) HDAC1HDAC6KMT2ALMNAALDH1A1
SCHEMBL4672374 0.83 SLC40A1 (0.36) KMT2ALMNAALDH1A1TDP1MAPT
SCHEMBL4677732 0.82 HDAC1 (0.32) HDAC1HDAC6KMT2AALDH1A1TDP1
SCHEMBL4678623 0.82 HDAC1 (0.43) HDAC1HDAC6KMT2ALMNAMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC6 1000/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.